GUIAS HIPERTENSION ARTERIAL.indb - Scc

246
GUÍAS COLOMBIANAS PARA EL DIAGNÓSTICO
Y TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL
9. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids
and lipoproteins. Arch Intern Med 1988; 148: 1280-1288.
10. Luther R, Glasssman H, Estep C, Maurath C, Jordan D. The effects of terazosin
on blood pressure and serum lipids. Am Heart J 1989; 117: 842-847.
11. Leren TP. Doxazosin increases low density lipoprotein receptor activity. Acta
Pharmacol Toxicol 1985; 56: 269-272.
12. Stamler R, Stamler J, Gosch FC, Berkson DM, Dyer AR, Hershinow P. Initial
antihypertensive drug therapy: Final report of a randomized, controlled trial
comparing alpha-blocker and diuretic. Hypertension 1988; 12: 574-581.
13. Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG. Lipids and lipoproteins
during antihypertensive drug therapy. Comparison of doxazosin and atenolol in
a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension
1994; 24: 241-248.
14. Ferrara LA, Di Marino L, Russo O, Marotta T, Mancini M. Doxazosin and
captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-
Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 1993;
21: 97-104.
Revista Colombiana de Cardiología
Febrero 2007
15. Kasiske B, Ma J, Kalil R, Louis T. Effects of antihypertensive therapy on serum
lipids. Ann Intern Med 1995; 15: 133-141.
16. Ram C, Gonzalez D, Kulkarni P, Sunderajan P, Corbett J, Taylor A. Regression
of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. Am J
Med 1989; 86: 66-69.
17. Yasumoto K, Takata M, Yoshida K, Mikawa M, Tomoda F, Sasayama S. Reversal
of left ventricular hypertrophy by terazosin in hypertensive patients. J Hum
Hypertens 1990; 4: 13-18.
18. Corral J, Lopez N, Pecorelli A, Rincon L, Teran V. Doxazosin in the treatment of
mild or moderate essential hypertension: an echocardiographic study. Am Heart
J 1991; 121 (1pt 2): 352-356.
19. Kirby R. Profile of doxazosin in the hypertensive man with benign prostatic
hyperplasia. Br J Clin Pract 1994; (Supl) 74: 18-22.
20. Gillenwater J, Conn R, Chrysant S, et al. Doxazosin for the treatment of benign
prostatic hyperplasia in patients with mild to moderate essential hypertension:
a double-blind, placebo-controlled, dose-response multicenter study. J Urol
1995; 154: 110-115.